Nyrada Quarterly Activities Report & Appendix 4C

Highlights:
• Cholesterol-Lowering Program advances:
– New data from in vivo cholesterol study showed NYX-PCSK9i significantly increased plasma PCSK9 levels, supporting the mechanism of action of Nyrada’s compound
– Treatment with NYX-PCSK9i also significantly increased the number of receptors
responsible for removing cholesterol from the bloodstream, enhancing cholesterol
clearance from the body
– Composition of matter patent granted for PCSK9 inhibitor technology by the
United States Patent and Trademark Office (USPTO)
– Preclinical studies expected to be completed by mid-CY2022 ahead of Phase I firstin-
human study
• Brain Injury Program progress:
– Testing of NYR-BI01 in WRAIR’s Traumatic Brain Injury (TBI) animal model is
underway, with initial results expected before the end of the year
– Phase I first-in-human study anticipated to commence second half of CY2022
• Robust cash position of A$12.4 million